Regulation of the master regulator FOXM1 in cancer.

Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, Hu CJ, Bai JY. · 2018

Read Regulation of the master regulator FOXM1 in cancer. by Liao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, Hu CJ, Bai JY. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6134757.txt.

Introduction

Liao and co-authors wrote a review in Cell Communication and Signaling on the cancer regulator FOXM1. FOXM1 is a protein that switches genes on during cell growth. It is found at high levels in most human cancers. High levels point to a poor outlook for patients. How it goes off track was not fully clear.

The review sums up the three layers that control FOXM1. Gene activity sets how much is made. Small RNAs trim its message after that. Chemical tags then alter the finished protein. The authors say mapping these controls can guide new cancer drugs. FOXM1 was named Molecule of the Year back in 2010.

Catalog record

CREATORLiao GB, Li XZ, Zeng S, Liu C, Yang SM, Yang L, Hu CJ, Bai JY.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6134757

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Regulation of the master regulator FOXM1 in cancer By Guo-Bin Liao, Xin-Zhe Li, Shuo Zeng, Cheng Liu, Shi-Ming Yang, Li Yang, Chang-Jiang Hu, Jian-Ying Bai Published in: Cell Communication and Signaling : CCS DOI: 10.1186/s12964-018-0266-6 ABSTRACT FOXM1 (forkhead box protein M1) is a critical proliferation-associated transcription factor that is widely spatiotemporally expressed during the cell cycle. It is closely involved with the processes of cell proliferation, self-renewal, and tumorigenesis. In most human cancers, FOXM1 is overexpressed, and this indicates a poor prognosis for cancer patients. FOXM1 maintains cancer hallmarks by regulating the expression of target genes at the transcriptional level. Due to its potential role as molecular target in cancer therapy, FOXM1 was named the Molecule of the Year in 2010. However, the mechanism of FOXM1 dysregulation remains indistinct. A comprehensive understanding of FOXM1 regulation will provide novel insight for cancer and other diseases in which FOXM1 plays a major role. Here, we summarize the transcriptional regulation, post-transcriptional regulation and post-translational modifications of FOXM1, which will provide extremely important implications for novel strategies targeting FOXM1. BACKGROUND Forkhead box M1 (FOXM1), previously named HNF-3, HFH-11 or Trident, is a transcription factor of the Forkhead box (Fox) protein superfamily which is defined by a conserved winged helix DNA-binding domain1 [1]. The human FOXM1 gene consists of 10 exons, of which exons Va and VIIa can be alternatively spliced [2]. In the past, VIIa was treated as a repressor until a novel isoform (FOXM1d) that could promote the epithelial–mesenchymal transition (EMT) and metastasis by activating ROCKs in colorectal cancer was identified [3, 4]. Accordingly, there are four isoforms of human FOXM1 identified to date (Fig. 1a). FOXM1a contains both exons Va and VIIa and lacks transactivation activity, while the rest of the three, FOXM1b (which contains neither exon Va nor VIIa), FOXM1c (no VIIa) and FOXM1d (no Va) are transcriptionally active. The FOXM1 protein contains a conserved forkhead DNA-binding domain (DBD), an N-terminal repressor domain (NRD), and a C-terminal transactivation domain (TAD). The transactivation activity of TAD can be suppressed by direct interaction with the NRD [5, 6]. In addition, murine FOXM1 splice variants display the same DNA-binding specificity as human FOXM1 and bind to DNA-binding sites with the consensus sequence 5′-A-C/T-AAA-C/ T-AA-3’ [7]. The study of murine FOXM1 may also be applied to human FOXM1. For example, it has been demonstrated that Gli1 regulates FOXM1 in murine stem cells [8]. In human basal cell carcinomas and colorectal cancer cells, FOXM1 is also a direct target of Gli1 [9, 10]. This may be due to the evolutionary conservation between the DNA binding domain of both human and murine FOXM1, suggesting the FOXM1 of the two species may share target genes. As such, investigating the regulation of murine FOXM1 may provide significant implications into the dysregulation of human FOXM1. Furthermore, a mouse model is a suitable experimental model for the development of novel FOXM1 inhibitors.Fig. 1Genomic structure and coding isoforms in the FOXM1 gene and transcription factor binding sites in FOXM1 promoter region. a. Genomic structure and coding isoforms of the FOXM1 gene. b. Schematic diagram of transcription factor binding sites during FOXM1 promoter region. Green: activator, red: repressor, purple: cis-acting element could be bound by both activator and repressor FOXM1 is detected primarily in progenitor and regenerating tissues, as well as tumor cells, which are all highly proliferative [11]. As a classic proliferation-associated transcription factor, FOXM1 directly or indirectly activates the expression of target genes at the transcriptional level and exhibits a spatiotemporal pattern whose dysregulation is involved in almost all hallmarks of tumor cells [3, 12]. Increased expression of FOXM1 is observed in a variety of human cancers, such as ovarian cancer, breast cancer, prostate cancer, hepatoma, angiosarcoma, colorectal cancer, melanoma, lung cancer, and gastric cancer [13–21], which is consistent with the results obtained from the TCGA database (Fig. 2). Inhibition of FOXM1 in cancer cells leads to decreased cell proliferation and migration, metastasis, angiogenesis, EMT, and drug resistance [22–26]. Furthermore, a recent meta-analysis revealed that elevated FOXM1 expression is related to poor prognosis in most solid tumors [27], which is also further confirmed by the TCGA database (Fig. 3) [28]. These results clearly showed the important role of FOXM1 in tumorigenesis and cancer development. Therefore, FOXM1 has been identified as a potential therapeutic target for the treatment of cancers. Although a few drugs and inhibitors have been shown to be effective at inhibiting the activity of FOXM1 in vitro, they’ve yet to pass successfully into clinical use [29]. This is likely due in major part to the poor current understanding of the regulation of FOXM1. Hence, a comprehensive review of FOXM1 regulation will thus contribute to the extensive effort and research into the gene as a therapeutic target for a number of FOXM1-dependent conditions, such as the cancers mentioned previously.Fig. 2FOXM1 expression profile from the TCGA database. The FOXM1 transcript per million are presented in differernt cancers and corresponding normal tissues, including ulterine corpus endometrial carcinoma (a), thyroid carcinoma (b), stomach adenocarcinoma (c), rectum adenocarcinoma (d), prostate adenocarcinoma (e), pheochromocytoma and paraganglioma (f), lung squamous cell carcinoma (g), lung adenocarcinoma (h), kidney renal clear cell carcinoma (i),kidney renal papillary cell carcinoma (j), kidney chromophobe (k), head and neck squamous cell carcinoma (l), glioblastoma multiforme (m), esophageal carcinoma (n), colon carcinoma (o), cholangiocarcinoma (p), cervical squamous carcinoma (q), breast invasive carcinoma (r), liver hepatocellular carcinoma (s), bladder urothelial carcinoma (t)Fig. 3Kaplan–Meier analyses of overall survival according to FOXM1 expression levels in different cancer suffers, including adrenocortical carcinoma (a), glioma (b), colon adencarcinoma (c), kidney chromophobe (d),kidney renal clear cell carcinoma (e),kidney renal papillary cell carcinoma (f),liver hepatocellular carcinoma (g),lung adenocarcinoma (h),ulterine corpus endometrial carcinoma (m),uveal melanoma (n) In this review, we provide an overview of how FOXM1 is regulated and focus on the transcriptional, post-transcriptional, post-translational, and protein-protein/RNA interaction levels. Though many biomolecules regulate the expression of FOXM1, we emphasize the biomolecules that directly interact with or modify the promoter, RNA, or protein of FOXM1. At the same time, we will discuss briefly the pharmacological inhibition of FOXM1. TRANSCRIPTIONAL REGULATION OF FOXM1 The core promoter regions of the FOXM1 gene contain several classic regulatory elements, such as E-boxes, and other cis-acting elements that can function as responsive elements to other transcription factors. Here, we mainly discuss the transcription factors that directly bind to the promoter regions (which are verified by electrophoretic mobility shift assays and/or chromatin immunoprecipitation assays) (Fig. 1b). Most responsive elements are located adjacent to FOXM1’s transcriptional start sites, though the furthest element is found approximately 2000 bp away. More than 75% of these binding sites act as cis-activation elements, but they do not all function through the same basic mechanisms. For example, glioma-associated oncogene homolog 1 (Gli1), CCCTC-binding factor (CTCF), cAMP responsive element-binding protein (CREB), signal transducer and activator of transcription 3 (STAT3), and E2F interact directly with their binding sites and upregulate FOXM1 expression [9, 30–34]. In human colorectal cancer (CRC), Gli1 regulates FOXM1 by directly binding to its promoter at BS4 (GCCCACCCA), which contributes to the proliferation of CRC cells [9]. The DNA-binding protein, CTCF, may regulate the motility and invasiveness of primary hepatocellular carcinoma (HCC) cells via interaction with the CTCF-binding site(s) located in the proximal

Read the complete text